Cargando…

Challenges Posed by Immune Responses to AAV Vectors: Addressing Root Causes

Host immune responses that limit durable therapeutic gene expression and cause clinically significant inflammation remain a major barrier to broadly successful development of adeno-associated virus (AAV)-based human gene therapies. In this article, mechanisms of humoral and cellular immune responses...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamilton, Bradley A., Wright, J. Fraser
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8168460/ https://www.ncbi.nlm.nih.gov/pubmed/34084173 http://dx.doi.org/10.3389/fimmu.2021.675897

Ejemplares similares

T Cell-Mediated Immune Responses to AAV and AAV Vectors
por: Ertl, Hildegund C. J.
Publicado: (2021)

Human Immune Responses to Adeno-Associated Virus (AAV) Vectors
por: Ronzitti, Giuseppe, et al.
Publicado: (2020)

Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside
por: Ferreira, Valerie, et al.
Publicado: (2014)

Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors
por: Basner-Tschakarjan, Etiena, et al.
Publicado: (2014)

Humoral Immune Response to AAV
por: Calcedo, Roberto, et al.
Publicado: (2013)

Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive Patients
por: Gross, David-Alexandre, et al.
Publicado: (2022)

Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential Solutions
por: Basner-Tschakarjan, Etiena, et al.
Publicado: (2014)

AAV vector production: Troublesome host innate responses in another setting
por: Wright, J. Fraser
Publicado: (2023)

AAV vector production: Troublesome host innate responses in another setting
por: Wright, J. Fraser
Publicado: (2023)

AAV Vectors Vaccines Against Infectious Diseases
por: Nieto, Karen, et al.
Publicado: (2014)

Innate Immune Responses to AAV Vectors
por: Rogers, Geoffrey L., et al.
Publicado: (2011)

Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions
por: Weber, Thomas
Publicado: (2021)

Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood
por: Smith, Corinne J., et al.
Publicado: (2022)

Effect of CpG Depletion of Vector Genome on CD8(+) T Cell Responses in AAV Gene Therapy
por: Bertolini, Thais B., et al.
Publicado: (2021)

Mapping the AAV Capsid Host Antibody Response toward the Development of Second Generation Gene Delivery Vectors
por: Tseng, Yu-Shan, et al.
Publicado: (2014)

A versatile toolkit for overcoming AAV immunity
por: Li, Xuefeng, et al.
Publicado: (2022)

Product-Related Impurities in Clinical-Grade Recombinant AAV Vectors: Characterization and Risk Assessment
por: Wright, J. Fraser
Publicado: (2014)

VectorMOD: Method for Bottom-Up Proteomic Characterization of rAAV Capsid Post-Translational Modifications and Vector Impurities
por: Rumachik, Neil G., et al.
Publicado: (2021)

Immune Response Mechanisms against AAV Vectors in Animal Models
por: Martino, Ashley T., et al.
Publicado: (2019)

Novel Combinatorial MicroRNA-Binding Sites in AAV Vectors Synergistically Diminish Antigen Presentation and Transgene Immunity for Efficient and Stable Transduction
por: Muhuri, Manish, et al.
Publicado: (2021)

Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?
por: Zhan, Wei, et al.
Publicado: (2021)

A strategy for high antibody expression with low anti-drug antibodies using AAV9 vectors
por: Davis-Gardner, Meredith E., et al.
Publicado: (2023)

Targeting the Root Cause of Mucopolysaccharidosis IIIA with a New scAAV9 Gene Replacement Vector
por: Bobo, Tierra A., et al.
Publicado: (2020)

Art–science multidisciplinary collaborations to address the scientific challenges posed by COVID-19
por: de la Fuente, José
Publicado: (2022)

Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial
por: Vandamme, Céline, et al.
Publicado: (2017)

Immunogenicity and toxicity of AAV gene therapy
por: Ertl, Hildegund C. J.
Publicado: (2022)

Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
por: Rapti, Kleopatra, et al.
Publicado: (2021)

AAV-8 and AAV-9 Vectors Cooperate with Serum Proteins Differently Than AAV-1 and AAV-6
por: Denard, Jérôme, et al.
Publicado: (2018)

Proteomics Analysis of Co-Purifying Cellular Proteins Associated with rAAV Vectors
por: Dong, Biao, et al.
Publicado: (2014)

Systemic and local immune responses to intraocular AAV vector administration in non-human primates
por: Ail, Divya, et al.
Publicado: (2022)

Deep Parallel Characterization of AAV Tropism and AAV-Mediated Transcriptional Changes via Single-Cell RNA Sequencing
por: Brown, David, et al.
Publicado: (2021)

Editorial: Induction of immune tolerance: addressing unmet medical need in immune mediated diseases and immune responses to biologics
por: Rosenberg, Amy S., et al.
Publicado: (2023)

Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A
por: Samelson-Jones, Benjamin J., et al.
Publicado: (2020)

Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors
por: Reul, Johanna, et al.
Publicado: (2019)

Editorial: “AAV Gene Therapy: Immunology and Immunotherapeutics”
por: Martinez-Navio, José M., et al.
Publicado: (2021)

Immunology of AAV-Mediated Gene Transfer in the Eye
por: Willett, Keirnan, et al.
Publicado: (2013)

Editorial: Immunogenicity and toxicity of AAV gene therapy
por: Bradbury, Allison, et al.
Publicado: (2023)

Syngeneic AAV Pseudo-particles Potentiate Gene Transduction of AAV Vectors
por: Wang, Qizhao, et al.
Publicado: (2016)

Intra-articular delivery of AAV vectors encoding PD-L1 attenuates joint inflammation and tissue damage in a mouse model of rheumatoid arthritis
por: Li, Wenjun, et al.
Publicado: (2023)

Targeting multiple myeloma with nanobody-based heavy chain antibodies, bispecific killer cell engagers, chimeric antigen receptors, and nanobody-displaying AAV vectors
por: Hambach, Julia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_aru9fqprb800dql9igir1knirb